The antihypertensive effects of quercetin in a salt-sensitive model of hypertension

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 3, 2008, Pages 239-245

  Mackraj, I ^a   Govender, T ^a   Ramesar, S ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Dahl rats; Quercetin; Salt sensitive hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN I; CAPTOPRIL; DIMETHYL SULFOXIDE; QUERCETIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; HYPERTENSION; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINE VOLUME;

ALDOSTERONE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; DIMETHYL SULFOXIDE; DISEASE MODELS, ANIMAL; HYPERTENSION; KIDNEY; MALE; QUERCETIN; RATS; RATS, INBRED DAHL; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY;

EID: 41349100106     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318162011f     Document Type: Article

References (42)

1. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood). 2007;26:13-24.
2. Mendis S. Challenges for the management of hypertension in lowresource settings. Ethn Dis. 2003;13:S67-S70.
3. Mulholland DA. The future of ethnopharmacology: a southern African perspective. J Ethnopharmacol. 2005;100:124-126.
4. Rayner B. The prevalence of microalbuminuria and ECG left ventricular hypertrophy in hypertensive patients in private practices in South Africa. Cardiovasc J S Afr. 2006;17:245-249.
5. Gaziano TA, Cohen DJ, Weinstein MC, et al. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112:3569-3576.
6. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res. 2004;24:851-874.
7. Hakkinen SH. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem. 1999;47:2274-2279.
8. van Beek TA. Chemical analysis of Ginkgo biloba leaves and extracts. J Chromatogr A. 2002;967:21-55.
9. Hertog MG. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995;155:381-386.
10. Hertog MG. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007-1011.
11. Xing N. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001;22:409-414.
12. Ferry DR. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996;2:659-668.
13. Duarte J. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol. 2001;133:117-124.
14. Sanchez M. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens. 2006;24:75-84.
15. Ajay M. Direct effects of quercetin on impaired reactivity of spontaneously hypertensive rat aortae: comparative study with ascorbic acid. Clin Exp Pharmacol Physiol. 2006;33:345-350.
16. Yamamoto Y, Oue E. Antihypertensive effect of quercetin in rats fed with a high-fat high-sucrose diet. Biosci Biotechnol Biochem. 2006;70:933-939.
17. Aoi W. Flavonoid-induced reduction of ENaC expression in the kidney of Dahl salt-sensitive hypertensive rat. Biochem Biophys Res Commun. 2004;315:892-896.
18. Guyton A, Hall J. Textbook of Medical Physiology. 9th ed ed. Philadelphia: W.B. Saunders; 1999.
19. Duncan AC, Jager AK, van Staden J. Screening of Zulu medicinal plants for angiotensin converting enzyme (ACE) inhibitors. J Ethnopharmacol. 1999;68:63-70.
20. Hackl LP. Inhibition of angiotesin-converting enzyme by quercetin alters the vascular response to brandykinin and angiotensin I. Pharmacology. 2002;65:182-186.
21. Nagata K. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension. 2002;40:168-174.
22. Rasmussen R. Quantification on the LightCycler. In: Rapid Cycle Realtime PCR, Methods and Applications. Meuer S, Nakagawara K, Eds. Heidelberg: Springer Press; 2001:21-34.
23. Singh R. Sanguinarine downregulates AT1a gene expression in a hypertensive rat model. J Cardiovasc Pharmacol. 2006;48:14-21.
24. Schalasta G. Fast and type-specific analysis of herpes simplex virus types 1 and 2 by rapid PCR and fluorescence melting-curve-analysis. Infection. 2000;28:85-91.
25. Shanmugam S, Sandberg K. Ontogeny of angiotensin II receptors. Cell Biol Int. 1996;20:169-176.
26. Guyton AC. Blood pressure control-special role of the kidneys and body fluids. Science. 1991;252:1813-1816.
27. Hall JE. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol. 1986;250:R960-R972.
28. Mackraj I. Regulation of renal alpha 2-adrenoceptor activity in Dahl salt-sensitive rats by dietary sodium changes. Methods Find Exp Clin Pharmacol. 1998;20:755-760.
29. Carey RM, Siragy HM. Newly recognized components of the reninangiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-271.
30. Miyata N, Park F, Li X. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol. 1999;277:F437-F446.
31. Navar L, Harrison-Bernard L, Nishiyama A. Regulation of intrarenal angiotensin II in hypertension. Hypertension. 2002;39:316-322.
32. Mitchell K, Braam B, Navar L. Hypertensinogenic mechanisms mediated by renal actions of renin-angiotensin system. Hypertension. 1992;19:18-27.
33. Barac-Nieto M, Spitzer A. The relationship between renal metabolism and proximal tubule transport during ontogeny. Pediatr Nephrol. 1988;2:356-367.
34. Otsuka F. Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in Dahl salt-sensitive rats. Am J Physiol. 1998;274:R1797-R1806.
35. Regitz-Zagrosek V. Molecular biology of angiotensin receptors and their role in human cardiovascular disease. J Mol Med. 1996;74:233-251.
36. Moreira AJ. Quercetin prevents oxidative stress and NF-kappaB activation in gastric mucosa of portal hypertensive rats. Biochem Pharmacol. 2004;68:1939-1946.
37. Ruiz-Ortega M. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol. 2001;158:1743-1756.
38. Ruiz-Ortega M. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 1998;161:430-439.
39. Morrissey JJ, Klahr S. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int. 1997;52:926-933.
40. Aguilera G. Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat. Mol Cell Endocrinol. 1992;90:53-60.
41. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-556.
42. Beutler KT. Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension. 2003;41:1143-1150.